Belatacept

Belatacept
Names
Trade namesNulojix
Clinical data
Drug classT cell activation inhibitor[1]
Main usesKidney transplant[2]
Side effectsLow red blood cells, diarrhea, urinary tract infection, swelling, constipation, fever, cough, nausea, low or high potassium[2]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • AU: C
  • US: N (Not classified yet)
    Routes of
    use    		Intravenous
    Typical dose5 to 10 mg/kg[3]
    External links
    AHFS/Drugs.comMonograph
    MedlinePlusa606016
    Legal
    License data
    Legal status
    • AU: S4 (Prescription only)
    • UK: POM (Prescription only)
    • US: ℞-only
    • EU: Rx-only

    Belatacept, sold under the brand name Nulojix, is a medication used to prevent rejection following a kidney transplant.[2] It is used with corticosteroids and mycophenolic acid.[3] Use in the United Kingdom is not generally recommended.[1] It is given by injection into a vein.[3]

    Common side effects include low red blood cells, diarrhea, urinary tract infection, swelling, constipation, fever, cough, nausea, and low or high potassium.[2] Other side effects may include infections, cancer, and posttransplant lymphoproliferative disorder.[4] It is a recombinant fusion protein which acts as a T cell activation inhibitor.[1][4]

    Belatacept was approved for medical use in the United States and Europe in 2011.[2][3] In the United Kingdom 250 mg costs the NHS about £355 as of 2021.[1] This amount in the United States is about 930 USD.[5]

    Medical uses

    Dosage

    It is initially given at a dose of 10 mg/kg at the time of surgery.[3] Further doses are than given at days 5, 14, and 28 and at 8 and 12 weeks.[3] Further doses of 5 mg/kg are than given every 4 weeks.[3]

    Chemistry

    It is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It differs from abatacept (Orencia) by only two amino acids.

    References

    1. 1 2 3 4 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 893. ISBN 978-0857114105.
    2. 1 2 3 4 5 "DailyMed - NULOJIX- belatacept injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 25 March 2021. Retrieved 8 January 2022.
    3. 1 2 3 4 5 6 7 "Nulojix". Archived from the original on 22 June 2021. Retrieved 8 January 2022.
    4. 1 2 "Belatacept Monograph for Professionals". Drugs.com. Archived from the original on 24 November 2020. Retrieved 8 January 2022.
    5. ↑ "Belatacept Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 8 January 2022.
    External sites:
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.